A Phase 1b/2 Dose-Escalation and Expansion Trial of NC-6300 (Nanoparticle Epirubicin) in Patients With Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft Tissue Sarcoma
Phase of Trial: Phase I/II
Latest Information Update: 26 Sep 2018
At a glance
- Drugs Epirubicin (Primary)
- Indications Soft tissue sarcoma; Solid tumours
- Focus Adverse reactions
- Sponsors NanoCarrier
- 18 Sep 2018 Planned primary completion date changed from 1 Jul 2018 to 1 Jul 2020.
- 31 Aug 2018 Biomarkers information updated
- 12 Oct 2017 Status changed from not yet recruiting to recruiting.